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ATP released from airway epithelial cells promotes puri-
nergic receptor-regulated mucociliary clearance activities
necessary for innate lung defense. Cell swelling-induced
membrane stretch/strain is a common stimulus that pro-
motes airway epithelial ATP release, but the mechanisms
transducing cell swelling into ATP release are incompletely
understood. Using knockdown and knockout approaches, we
tested the hypothesis that pannexin 1 mediates ATP release
from hypotonically swollen airway epithelia and investigated
mechanisms regulating this activity. Well differentiated pri-
mary cultures of human bronchial epithelial cells subjected to
hypotonic challenge exhibited enhanced ATP release, which
was paralleled by the uptake of the pannexin probe pro-
pidium iodide. Both responses were reduced by pannexin 1
inhibitors and by knocking down pannexin 1. Importantly,
hypotonicity-evoked ATP release from freshly excised tra-
cheas and dye uptake in primary tracheal epithelial cells were
impaired in pannexin 1 knockout mice. Hypotonicity-pro-
moted ATP release and dye uptake in primary well differen-
tiated human bronchial epithelial cells was accompanied by
RhoA activation and myosin light chain phosphorylation and
was reduced by the RhoA dominant negative mutant
RhoA(T19N) and Rho and myosin light chain kinase inhibi-
tors. ATP release and Rho activation were reduced by highly
selective inhibitors of transient receptor potential vanilloid 4
(TRPV4). Lastly, knocking down TRPV4 impaired hypotonic-
ity-evoked airway epithelial ATP release. Our data suggest
that TRPV4 and Rho transduce cell membrane stretch/strain
into pannexin 1-mediated ATP release in airway epithelia.
Themucociliary clearance process that removes foreign par-
ticles and pathogens from the airways is the primary innate
defense mechanism in the lung (1). Nucleotides and nucleo-
sides within the airway surface liquid (ASL)3 regulate key com-
ponents ofmucociliary clearance via activation of epithelial cell
surface purinergic receptors (2, 3). ATP activates the Gq-cou-
pled P2Y2 receptor that promotes mucin secretion and ciliary
beat frequency and regulates electrolyte transport andASL vol-
ume production by inhibiting sodium absorption (4–10) and
promoting cystic fibrosis transmembrane conductance regula-
tor and Ca2-activated Cl channel activity (11–16). Adeno-
sine, generated from the hydrolysis of ATP, activates the Gs-
coupled A2b receptor that promotes cyclic AMP-regulated
cystic fibrosis transmembrane conductance regulator Cl
channel activity (17) and increases cilia beat frequency (5).
Although ATP and adenosine are naturally occurring signaling
molecules in ASL (18–22), themechanisms of airway epithelial
ATP release into the ASL are poorly understood.
The lung epithelia exhibit a complex cellular composition,
and thus, several mechanisms and pathways are likely involved
in the release of nucleotides onto airway surfaces. Our recent
studieswith goblet-like cellmodels indicate thatATP and other
nucleotides are released concomitantlywithMUC5AC, a secre-
tory mucin, during Ca2-regulated exocytosis of mucin gran-
ules (23, 24). Thus, mucin-secreting granules constitute an
important source of ASL ATP, providing a pathway for para-
crine signaling to ciliated cells to hydrate secreted mucins (24).
A vesicular mechanism for nucleotide release may also operate
in non-mucous cells. For example, by selectively manipulating
the levels of expression of Golgi-resident nucleotide-sugar
transporters in 16HBE14o cells, a cell line thatmimics aspects
of ciliated epithelia, we demonstrated that theGolgi lumen is an
important source of extracellular UDP-sugar constitutively
released from cells (25). Although not formally demonstrated, a
similar mechanism may apply for the constitutive release of
ATP (26).
Mechanical forces during tidal breathing and coughing and
cell swelling during hypotonic gland secretions are ubiquitous
stimuli imparting robust ATP release in the airways, but the
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lial ATP release are not well defined (21, 22, 27–29). Recently,
Ransford et al. (30) reported that ATP release from hypotoni-
cally swollen primary cultures of human bronchial epithelial
(HBE) cells was nearly 60% inhibited by pannexin channel
blockers or by knocking down pannexin 1 via shRNA. Thus,
pannexin 1 is a candidate ATP release pathway in hypotonically
swollen HBE cells. However, regulatory signaling elements
transducing hypotonic/mechanical stress into ATP release
have not been identified. Moreover, the contribution of pan-
nexin 1 to the physiological release of ATP from native airways
is not known. We recently discovered that activation of lung
epithelial cell G protein-coupled protease-activated receptors
(PAR) resulted in enhanced release of ATP and uptake of pro-
pidium iodide in a Rho-dependent manner (31), suggesting a
link between Rho activation and the opening of a propidium
iodide-permeable plasma membrane channel. In the present
study, we tested the hypothesis that ATP release fromhypoton-
ically stimulated airway epithelial cells involves Rho-regulated
opening of pannexin 1 channels and used a pannexin 1 knock-
outmousemodel to assess the contribution of pannexin 1 to the




,-methylene ATP, carbenoxolone, flufenamic acid, pro-
pidium iodide, luciferase from Photinus pyralis, and anti-
tubulin monoclonal antibody were obtained from Sigma.
Luciferin and monoclonal antibodies against Golgi proteins
G-p28 andG-p84were obtained fromBDBiosciences. The Rho
activation assay biochem kit was purchased from Cytoskeleton
(Denver, CO). ML-7 and H1152 were purchased from Calbi-
ochem. The TRPV4 inhibitor HC67047 (32) was a kind gift
from Drs. David Clapham and Magdalene Moran (Hydra Bio-
sciences). The pannexin 1 blocking peptide WRQAAFVDSY
(10Panx1) (33) and its scrambled version, (SCRPanx1) SADYR-
VAFWQ, were synthesized at the University of North Carolina
Microprotein Sequencing and Peptide Synthesis Facility. Anti-
bodies directed against the carboxyl-terminal tails of human
andmouse pannexin 1, respectively, have been previously char-
acterized (34). Other chemicals were from sources reported
previously (19, 35).
Generation of Pannexin 1 Knockout Mice—Pannexin 1-tar-
geted heterozygous C57B1/6N mice were obtained from the
Knockout Mouse Project (KOMP) (36), which generates dis-
ruption of pannexin 1 by insertion of a strong splice acceptor
site between exons 1 and 2 (pannexin1tm1a(KOMP)Wtsi).
Heterozygous mice were bred to produce homozygous pan-
nexin 1-deficient animals. All animal studies were approved by
the Institutional Animal Care and Use Committee and were
performed according to principles outlined by theAnimalWel-
fare and theNational Institutes ofHealth guidelines for the care
and use of animals in biomedical research. Genotyping was
conducted using primers for WT and targeted alleles (supple-
mental Table 1). Pannexin 1 expression was assessed by RT-
PCR andWestern blot analysis, as indicated further below (sup-
plemental Figs. 4 and 5). Heterozygous pannexin 1-targeted
mice are fertile and produce homozygous-targeted mice at the
expected frequency. Homozygous deletion of pannexin 1 has
not caused grossly observed abnormalities.
All experiments involving animals were performed in
accordance with the protocols approved by the UNC Institu-
tional Animal Care and Use Committee.
Cell Culture and Incubations—Primary cultures of polarized,
well differentiated HBE (WD-HBE) cells were provided by the
UNC Cystic Fibrosis Center Tissue Culture Core. WD-HBE
cells were grown on 12-mm Transwell supports (Costar) and
maintained at an air-liquid interface, as described previously
(37). A549 lung epithelial cells were grown to confluence on
plastic dishes as described previously (31). Calu-3 cells were
grown as polarized monolayers, as described (19). Primary cul-
tures of mouse trachea epithelial (MTE) cells were grown on
6-mm coated supports, as described previously (38).
Cells were rinsed twice with Hanks’ balanced salt solution
(HBSS) supplemented with 1.6 mM CaCl2, 1.8 mM MgCl2,
and 25 mM HEPES (pH 7.4) (HBSS) and preincubated as
indicated in the corresponding assay sections. The hypo-
tonic challenge was applied by gently replacing one third of
the volume of the extracellular solution with a HEPES-buff-
ered (pH 7.4) solution containing 1.6 mM CaCl2 and1.8 mM
MgCl2, thus reducing the solution tonicity to 200 mOsm, as
described previously (21). A saline-based (isotonic) solution
containing the above additions was used for volume replace-
ment in control cultures.
Measurement of ATP Release—ATP release was quantified
using the luciferin/luciferase assay, as described previously (31).
Calibration curves using known concentrations of ATP were
generated at the end of each experiment. None of the reagents
used during ATP release measurements interfered with the
luciferase reaction.
Uptake of Propidium Iodide—We have described this assay
in detail (31). Briefly, cultures were challenged for 5 min in
the presence of 20 M propidium iodide (addedmucosally on
polarized primary cultures). At the end of the incubation, the
bathing solution was replaced with HBSS containing 4%
paraformaldehyde. Acquisition of confocal images and
quantification of nuclei staining were performed on a Leica
SP5 confocal microscope as described (31). Alternatively, to
measure propidium iodide uptake in real time, WD-HBE cell
cultures were mounted on the microscope platform, and
propidium iodide was added. After a 5-min recording, cells
were challenged, and serial images were taken during an
additional 5 min. Confocal microscopy scanning in the xz
axis of WD-HBE and MTE cell cultures verified that nuclei
labeled with propidium iodide were localized in the most
lumenal cell layer of the cultures. In primary (multilayered)
cultures, total nuclei were quantified from the differential
interference contrast images. In A549 cells (monolayers),
total nuclei were assessed either from the differential inter-
ference contrast images or by quantifying propidium iodide
staining after permeabilizing the cells with 0.05% Triton
X-100. Both methods yield similar results.
RT-PCR Analysis—Total RNA was prepared using the
RNeasyMini Kit (Qiagen, Inc., Valencia, CA) and reverse-tran-
scribed using SuperScript III reverse transcriptase (Invitrogen).
Standard RT-PCRwas performed as described (31), except that
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45 thermocycles (rather than 35) were used to amplify Panx2
and Panx3 in WD-HBE cells. Amplified products were
sequenced at the UNC Genome Analysis. Semi-quantitative
PCR was performed in a LightCycler PCR machineR thermal
cycler, as described previously (31). Pannexin primers are
described in supplemental Table 1. Connexin primers were as
follows: forward, 5-GGGTTAAGGGAAAGAGCGACC-3
and reverse, 5-CCCCATTCGATTTTGTTCTGC-3.
siRNA—Oligonucleotides targeting human pannexin 1
(siRNA-70) and its scrambled control (supplemental Table 2)
were purchased from Dharmacon, Inc. A549 cells were trans-
fected with 1 g of oligonucleotide using the Amaxa Nucleo-
fector DeviceTM andCell LineNucleofectorKit T (Amaxa Bio-
systems, Gaithersburg, MD), following the manufacturer’s
instructions. Transfected cells were cultured in serum-supple-
mented DMEM for 48 h prior to assays.
shRNA—Lentiviral vector expression clones (pLKO1/puro-
mycin) containing shRNAs (supplemental Table 2) were
obtained from the Lenti-shRNA core facility of the UNC. Cells
were infected with the desired lentivirus (106cfu/35-mm dish)
and subsequently selected with 0.5 g/ml puromycin. Cells
were used within five passages post-infection.
Overexpression of RhoA(T19N)—A549 cells were trans-
fected with empty pcDNA3.1 vector or vector containing
RhoA(T19N) insert using the Amaxa Nucleofector DeviceTM
and used 48 h post-transfection, as described (31).
RhoA Pull-down Assay and MLC Phosphorylation—Mea-
surements of GTP-bound RhoAwere performed using the Rho
activation assay biochem kit (Rhoketing pull-down assay), as
described previously (31). Duplicated membranes were sepa-
rately blotted with anti-phospho-MLC(Ser-19) antibody or
anti-MLC antibodies (Cell Signaling Technology, Inc., Dan-
vers, MA), and immunoblots were revealed and quantified as
described (31). To minimize autocrine feedback via ATP
release, hypotonic stress-promoted Rho activation and MLC
phosphorylation were assessed in the presence of 5 units/ml
apyrase (31).
Cell Volume Regulation—Changes in cell height were mea-
sured to estimate cell volume changes, as described previously
(21). In brief, WD-HBE cells were loaded with 5 M calcein-
acetoxymethyl ester (AM) (Molecular Probes, Eugene, OR) for
30 min at 37 °C. The apical surface of cultures was equilibrated
for 10 min with HBSS, and the osmolarity of the solution was
reduced to 200 mOsm, as indicated above. Images of confocal
microscopy scanning in the xz axis were obtained every second
for the initial 15 s and then every 5 s for the next 75 s.
Perfusion of Mouse Tracheas—Tracheas were excised from
euthanizedmice (5–6 weeks old), cannulated/connected to a
peristaltic pump, and perfused under controlled flow rates
(50 l/min) for 90 min with HBSS to remove cell debris/
inflammatory cells, as described (39). After rinsing, effluents
were collected at 5-min intervals under isotonic conditions
followed by hypotonic (50% tonicity) perfusion conditions,
as indicated.
Data Analysis—Data were analyzed by Student’s t test or,
where indicated, analysis of variance with GraphPad InStat
software (21). Statistical significance was defined as p  0.05 or
p  0.01, as indicated.
RESULTS
Hypotonic Stress Promotes Pannexin 1-mediated Dye Uptake
and ATP Release—Pannexins and connexins form non-junc-
tional plasma membrane channels that, upon activation, allow
the passage of 1 kDa molecules, including ATP and small
molecular weight (MW) dyes (40–42). As an initial test for the
expression of functional pannexin channels on airway epithelial
cells, the uptake of the pannexin/connexin channel-permeable
reporter dye propidium iodide (31) was investigated. Pro-
pidium iodide displays low intrinsic fluorescence in solution,
but its fluorescence increases 20- to 30-fold upon binding to
nucleic acids. Resting cultures ofWD-HBE cells displayed neg-
ligible nuclear labeling with propidium iodide, but exposure of
cells to a hypotonic challenge resulted in enhanced uptake of
the dye, as judged by the sharp increase of nuclear fluorescence
(Fig. 1A). The time course of propidium iodide uptake in hypo-
tonically challengedWD-HBE cells was nearly identical to that
of hypotonicity-stimulated ATP release (Fig. 1B).
Both hypotonicity-stimulated propidium iodide uptake (Fig.
1C) and ATP release (D) were markedly impaired in the pres-
ence of 10 M carbenoxolone, a licorice root derivative that
preferentially inhibits pannexin channels over connexin hemi-
channels and volume-regulated anion channels (43–45). In
contrast, 100M flufenamic acid, a potent inhibitor of connexin
hemichannels that displays low affinity for pannexin 1 (43, 46),
had no significant effect on ATP release and propidium iodide
uptake in WD-HBE cells (Fig. 1, C and D).
The potential involvement of pannexin 1 in ATP release and
dye uptake was further tested by assessing the effect of the pan-
nexin 1-selective blocking peptide 10Panx1. 10Panx1 (30 M)
completely blocked the uptake of propidium iodide in hypoton-
ically challengedWD-HBE cells, whereas its scrambled control
peptide (scrPanx1) had a negligible effect (Fig. 1C). In parallel
experiments, 10Panx1 (but not scrPanx1) inhibited ATP release
(Fig. 1D). These results strongly suggest that pannexin 1 is an
important mediator of ATP release from WD-HBE cells. It is
worth noting, however, that inhibition of ATP release by
10Panx1 (50–60%) was less robust than the nearly 100% inhibi-
tion observed on dye uptake (compare Fig. 1,C andD), suggest-
ing that other mechanisms in addition to pannexin channel
activation contributed to ATP release from these cells.
An important control for these studies was to rule out the
potential effect of the pharmacological inhibitors on hypoto-
nicity-triggered cell swelling. As shown in Fig. 2, the extent of
hypotonic cell swelling was not affected by carbenoxolone,
although carbenoxolone delayed the regulatory volume
decrease (RVD) (Fig. 2, A and B). Similar to carbenoxolone,
10Panx1 had no effect on hypotonicity-induced cell swelling but
reduced RVD (supplemental Fig. 1). The inhibitory effect of
carbenoxolone and 10Panx1 on RVD likely reflected less ATP
release. That is, ATP released from swollen cells promotes P2Y2
receptor-mediated activation of intermediate-conductance
Ca2-dependent K channels, which are essential for the RVD
response (21, 47, 48). These results are consistent with the
notion that carbenoxolone and 10Panx1 acted downstream of
the hypotonic stress sensor but upstream of ATP release-
evoked RVD (21).
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RT-PCR analysis indicated that pannexin 1 is expressed in
WD-HBE cells (supplemental Fig. 2) as reported (30). Sequence
analysis of the PCR reaction product demonstrated the inser-
tion of ggt atg aac ata 66 bp upstream of the termination codon
of pannexin 1, suggesting that the 426 amino acid-long pan-
nexin 1b (GenBank accession number NP_056183.2 (49)) is the
major pannexin 1 subvariant expressed in HBE cells. Pannexin
2 (49) and pannexin 3 RNAs were weakly or not amplified,
respectively (supplemental Fig. 2). These results are consistent
with a previous report indicating that pannexin 1 is the major
pannexin subtype expressed in HBE cells (30).
Previously, we demonstrated that regulatory features associ-
ated with G protein-coupled receptor-promoted ATP release
from WD-HB cells, e.g. sensitivity to carbenoxolone, are also
present in lung epithelial carcinoma A549 cells, and that ago-
nist-evoked ATP release from A549 cells was accompanied by
carbenoxolone-sensitive uptake of propidium iodide (31).
Moreover, like WD-HBE cells, A549 cells displayed enhanced
propidium iodide uptake (supplemental Fig. 3A) and ATP
release (supplemental Fig. 3B) in response to a hypotonic chal-
lenge, which were inhibited by carbenoxolone and 10Panx1.
Therefore, given the suitability of A549 cells for siRNA oligo-
nucleotide transfection (31), we utilized siRNA approaches to
investigate the involvement of pannexin 1 in ATP release from
A549 cells. A549 cells transfected with siRNA-70 (supplemen-
tal Table 2), a pannexin 1 siRNA oligonucleotide that knocked
down pannexin 1 in various cell lines (40, 50) exhibited a 50%
reduction of pannexin 1 transcript levels (Fig. 3A). The siRNA
approach did not affect the expression of connexin 43 tran-
scripts (Fig. 3A). Pannexin 1 siRNA-transfected cells exhibited
reduced hypotonic challenge-promoted ATP release (Fig. 3B)
and propidium iodide uptake (C and D). A scrambled oligonu-
cleotide had no effect (Fig. 3).
As a complementary approach to the siRNA-70 studies,
shRNA lentiviral vectors (supplemental Table 2) were used in
A549 cells as well as airway epithelial Calu-3 Cells. A549 and
Calu-3 cells stably expressing shRNA-N1 (supplemental Table
2) exhibited a 66% reduction in pannexin 1 transcript levels,
FIGURE 1. Hypotonicity-induced dye uptake and ATP release in WD-HBE cells. A, the uptake of propidium iodide (PI) was assessed in real time in response
to a 33% hypotonic stress as described under “Experimental Procedures.” The images represent PI-associated nuclear fluorescence at T  0 and 60 s after the
hypotonic challenge. Scale bar  100 m. B, time course of hypotonic stress-promoted PI uptake (assessed as in A) and ATP release. Dye uptake is expressed
as the percent of nuclei displaying red fluorescence. Similar results were obtained in at least three separate experiments performed in quadruplicate. C and D,
WD-HBE cells were preincubated for 15 min with vehicle or with 10 M carbenoxolone (CBX), 100 M flufenamic acid (FFA), 30 M 10Panx1 or its scrambled
control (srcPanx1), and exposed for 5 min to either isotonic (Iso) or hypotonic solution containing vehicle (Veh) or the indicated reagent. The results are mean 
S.E., n  4. *, significant inhibition of hypotonic stress-evoked responses, p  0.001 (analysis of variance).
FIGURE 2. Hypotonicity induces cell swelling. Calcein-labeled WD-HBE cells were preincubated for 15 min with vehicle or 10 M carbenoxolone (CBX).
A, images of representative confocal microscopy scanning in the xz axis of cells undergoing hypotonic cell swelling. B, quantification of hypotonicity-elicited
cell volume changes. The data are mean  S.E. of three independent experiments performed in triplicate. *, significant difference from control RVD.
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relative to uninfected (WT) cells or empty vector-infected
(mock) cells. Importantly, shRNA-N1 reduced hypotonicity-
evoked ATP release in A549 cells and Calu-3 cells grown as
polarized cultures (supplemental Fig. 4B). Western blot analy-
sis of WT Calu-3 cells indicated strong immunoreactivity con-
sistent with pannexin 1 mobility (50 kDa (50)). Pannexin 1
immunoreactivity was markedly reduced in shRNA-N1-ex-
pressing but not in mock-infected Calu-3 cells (supplemental
Fig. 4C).
In sum, our results in Figs. 1–3 are in close agreement with
and expand recent observations by Ransford et al. (30), indicat-
ing that pharmacological inhibitors of pannexin 1 and pannexin
1 knockdown decreased ATP release and hypotonicity-stimu-
lated airway epithelia cells.
Next, we tested the hypothesis that pannexin 1 contributes to
physiological nucleotide release from native airways using a
pannexin 1-targeted mouse. RT-PCR analysis of mouse ear
punches and Western blot analysis of murine brain (the tissue
exhibiting the highest level of pannexin 1 immunoreactivity
(34)) verified the absence of pannexin 1 expression in the pan-
nexin 1 knockout mouse and reduced expression in pannexin
1  mice (supplemental Fig. 5, A and B). Western blot analysis
of primary cultures of MTE cells indicated a strong anti-pan-
nexin 1 immunoreactive double band of 50 kDa inWTMTE
cells that was completely absent in cells from a pannexin 1-de-
ficient mouse (Fig. 4A). Hypotonicity evoked propidium iodide
uptake in WT MTE cells but not in MTE cells from pannexin
1/ mice (Fig. 4B). Next, utilizing a perfusion approach (39,
51), we assessed ATP levels in luminal secretions from tracheas
excised fromWT versus pannexin 1 knockout mice under con-
trolled flow conditions. As shown in Fig. 4C, a baseline ATP
concentration of 2  1 nM was observed in tracheas from WT
FIGURE 3. Pannexin 1 mediates hypotonicity-induced ATP release in A549 cells. A549 cells were sham transfected (Control) or transfected with either
pannexin 1 siRNA oligonucleotides (siRNA) or its scrambled control, as described under “Experimental Procedures.” A, Panx1 siRNA decreased pannexin 1 (but
not connexin 43 (Cx43)). The data represent mean  S.E., n  4. B, ATP release was measured in A549 cells transfected as above and incubated for 5 min in
isotonic (Iso) or hypotonic (Hypo) solutions. The data represent mean  S.E. of three separate experiments performed in triplicate. C, representative images of
PI uptake assessed under the conditions described in B. Scale bar  100 m. D, quantification of PI uptake (mean  S.D., n  4). Similar results were obtained
in two independent experiments performed in quadruplicate. *, significantly different from control and scrambled, p  0.05.
FIGURE 4. Reduced ATP release from pannexin 1/ tracheas. A, Western blot analysis of cultured MTE cells (15 g prot) from WT and pannexin 1/
littermates. Molecular weight standards are indicated on the right (in kDa). G-p28, a Golgi marker, was used as loading control. B, propidium iodide uptake was
performed in WT and pannexin 1-deficient MTE cells incubated for 5 min under isotonic or hypotonic conditions. C, tracheas excised from WT and pannexin
1/ littermates were perfused (50 l/min) with HBSS (isotonic) for 45 min. Tonicity was reduced to 50% (hypotonic), as indicated. The data (mean  S.D., n 
3) is representative of two independent experiments performed with separate litters.
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mice under isotonic perfusion that imparts minor shear stress (50
l/min0.08dyn/cm2 (22, 39, 52)).ATP levels increased sharply,
up to 12.6  4 nM, after 5 min of hypotonicity and gradually
decayed to initial values after 30 min. In contrast, tracheas from
pannexin 1/ animals exhibited slightly decreased baseline ATP
levels (1  0.4 nM) and strikingly impaired hypotonicity-stimu-
lated ATP release (3.6  1.8 nM at peak (Fig. 4C)).
Having demonstrated that cell swelling-promoted ATP
release is associated with pannexin 1-mediated dye uptake, we
assessed the potential reversibility of this phenomenon. WD-
HBE cells exposed to hypotonic solution exhibited enhanced
propidium iodide uptake only if the dyewas added concurrently
with the hypotonic challenge (Fig. 5, a and b). That is, no
changes in propidium iodide uptake were observed if the dye
was added to cells after the isotonic conditions were restored
(Fig. 5, c and d). Similar results were observed in A549 cells
(supplemental Fig. 6). Thus, opening of the propidium iodide
uptake permeable channel/pore during hypotonic shock re-
flected a transient (i.e. regulated) phenomenon rather than irre-
versible plasma membrane damage.
Collectively, the data described above indicate that pannexin
1 contributes to the regulated release of ATP from hypotonic
stress-stimulated airway epithelial cells.
Rho GTPases Regulate ATP Release from Hypotonically
Stimulated Airway Epithelial Cells—On the basis of recent
studies suggesting that Rho GTPases are important regula-
tors of ATP release in cells stimulated with the serine prote-
ase thrombin (31, 53), we hypothesized that Rho signaling is
also involved in ATP release from hypotonic stress-stimu-
lated WD-HBE cells. Therefore, the effects of inhibitors of
Rho kinase and Rho kinase downstream effectors were inves-
tigated in WD-HBE cultures subjected to hypotonic stress.
Hypotonic challenge-promoted ATP release was reduced in
the presence of H1152 (Fig. 6A), a highly selective Rho kinase
inhibitor (54, 55). The regulatory domain of MLC is a major
downstream effector of Rho kinase. By phosphorylating and
inactivating MLC phosphatase, Rho kinase facilitates MLC
phosphorylation by MLC kinase (56). Consistent with the
possibility that MLC phosphorylation was involved in ATP
release from hypotonicity-stimulated HBE cells, the MLC
kinase inhibitor ML-7 markedly reduced ATP release from
these cells (Fig. 6A). ML-7 and H1152 had no effect on hypo-
tonic stress-elicited cell swelling, although, like carbenox-
olone and 10Panx1, they delayed RVD (supplemental Fig. 1).
These results suggest that hypotonic stress-promoted Rho/
Rho kinase activation and enhanced MLC phosphorylation
are upstream of ATP release.
To directly test whether hypotonic stress induced Rho
activation and MLC phosphorylation in WD-HBE cells,
RhoA-GTP and MLC phosphorylation were measured by
pull-down assays and phospho-MLC(Ser-19) immunoblots,
FIGURE 5. Dye uptake in WD-HBE cells reflects a reversible phenomenon.
Representative images (A) and quantification (B) of dye uptake in WD-HBE
cells that were incubated for 5 min with isotonic (iso) or hypotonic (hypo)
solutions in the presence of propidium iodide (a and b) or in its absence (c and
d). Isotonicity was restored in d, and propidium iodide subsequently added to
c and d for an additional 5 min. The images are representative of two inde-
pendent experiments performed in quadruplicate. Scale bar  100 m.
Nuclei staining was quantified (B) and expressed as mean  S.E. *, signifi-
cantly different from a, p  0.01.
FIGURE 6. Hypotonicity-induced ATP release in WD-HBE cells is associated with enhanced Rho activation and MLC phosphorylation. A, WD-HBE cells
were preincubated for 45 min with 1 M H1152 or 1 M ML-7, and ATP release was measured after a 5-min incubation in hypotonic solution (Hypo) or isotonic
control (Iso). n  4. *, significantly different from Ctrl/Hypo, p  0.05. B, representative Western blot for RhoA (left panel) and quantification of RhoA activation
(right panel, mean  S.E., n  7) in response to a 5-min hypotonic challenge. C, effect of 1 M H1152 or 1 M ML-7 on hypotonicity-promoted MLC phosphor-
ylation. A representative Western blot analysis and the quantification of phosphorylated MLC (MLCp) are shown in the left and right panels, respectively
(mean  S.D., n  4). *, significantly different from Vehicle/Hypo, p  0.05.
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respectively. As illustrated in Fig. 6, B and C, hypotonic
stress promoted RhoA activation and enhanced MLC phos-
phorylation, respectively, relative to control cells. As pre-
dicted, H1152 and ML-7 reduced MLC phosphorylation in
hypotonicity challenged HBE cells (Fig. 6C). Control exper-
iments indicated that H1152 and ML-7 had no effect on
hypotonicity-promoted RhoA-GTP formation, i.e. upstream
of Rho kinase (supplemental Fig. 7).
Although the experiments described above indicated that
RhoA was activated in response to a hypotonic challenge, evi-
dence that Rho activation is involved in ATP release has relied
exclusively on pharmacological inhibitors. To more conclu-
sively assess the involvement of Rho inATP release, the effect of
a dominant negative mutant of RhoA, RhoA(T19N) (31), was
examined. A549 cells transiently transfected with RhoA(T19N)
cDNA displayed reduced hypotonic shock-evoked ATP release
relative to empty vector-transfected cells (Fig. 7A). As expected,
RhoA activation and MLC phosphorylation were impaired in
A549 cells transfected with RhoA(T19N) (Fig. 7, B and C).
Rho Signaling Regulates Dye Uptake in Airway Epithelial
Cells—Having determined that ATP release from hypotonic
stress-stimulated cells reflects a Rho-dependent process
(Figs. 6 and 7) and is associated with pannexin 1 activation
(Figs. 1–5), the potential link between Rho signaling and
pannexin channel opening was examined. Both the Rho
kinase inhibitor H1152 and the MLC kinase inhibitor ML-7
caused a nearly complete inhibition of hypotonic challenge-
promoted propidium iodide uptake in WD-HBE cells (Fig. 8,
A and B). Moreover, transfection of A549 cells with
RhoA(T19N) markedly reduced the uptake of propidium
iodide in these cells (Fig. 8C).
TRPV4 as a Potential Upstream Effector of ATP Release—
The TRPV4 channel is a broadly expressed cation channel
that acts as a sensor of various physical stimuli such as heat,
osmotic stress, shear stress, and stretch (57–59). Relevant to
our study, it has been reported recently that TRPV4 medi-
ated ATP release in response to osmotic stress in the thick
ascending limb of the renal medulla (60) and in stretch-
stimulated urothelia (61). Because TRPV4 is abundantly
expressed in the airways (62, 63), we examined the possibility
that TRPV4 transduces hypotonic stress into Rho/pannexin
1-mediated ATP release in airway epithelia. An initial assess-
ment of this hypothesis indicated that ruthenium red (10
M), a general inhibitor of TRPV channels, significantly
reduced (by 50%) hypotonic stress-promoted ATP release
in WD-HBE cells (Fig. 9A). Moreover, HC67047, a potent
and highly selective inhibitor of TRPV4 (32), markedly
impaired ATP release (Fig. 9A), dye uptake (B), and RhoA
activation in hypotonicity-challenged WD-HBE cells (C).
Control experiments showed that HC67047 did not affect
hypotonic stress-induced cell swelling (supplemental Fig. 1).
Altogether, the data indicated that the target of HC67047
was downstream of the cell volume change and triggered by
the osmotic swelling.
To more definitively assess the involvement of TRPV4 in
hypotonicity-evokedATP release, A549were infectedwith len-
tiviruses bearing TRPV4 shRNAs (supplemental Table 2).
shRNA-E12 reduced TRPV4 transcript levels to less than 20%
of control cells, whereas other shRNAs caused only partial
reduction (shRNA-F12, 43% reduction) or no reduction at all
(shRNA-F11). Importantly, A549 cells stably expressing
shRNA-E12 exhibited reduced ATP release in response to
hypotonicity. shRNA-E12 virtually abolished the HC67047-
sensitive responses observed in these cells (supplemental Fig.
8A). Similar results were obtained with Calu-3 cells (supple-
mental Fig. 8B).
DISCUSSION
Our study demonstrates that pannexin 1 mediates ATP
release from hypotonic stress-activated airway epithelia, both
in vitro and ex vivo.We illustrated thatWD-HBE cells displayed
hypotonic stress-promoted uptake of the hemichannel probe
propidium iodide with kinetics overlapping that of ATP release
(Fig. 1). The non-selective hemichannel inhibitor carbenox-
FIGURE 7. Inhibition of RhoA activation reduces hypotonic stress-induced ATP release. A549 cells were transfected with empty vector or
RhoA(T19N), as indicated under “Experimental Procedures.” A, hypotonicity-elicited ATP release (mean  S.E., from three independent experiments
performed in quadruplicate; *, p  0.05). B and C, RhoA activation and phosphorylated MLC (MLCp) in response to hypotonic stress. Representative
Western blot analysis and quantifications (mean  S.E., n  4) are shown in the left and right panels, respectively. *, significantly different from empty
vector/Hypo, p  0.05.
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olone, the pannexin 1-selective blocking peptide 10Panx1, and
pannexin 1 RNAimarkedly decreased dye uptake in addition to
reducing ATP release (Figs. 1 and 3 and supplemental Figs. 3
and 4). Thus, pannexin 1 is functionally expressed at the human
airway epithelial plasma membrane, i.e. as an ATP- (and dye)-
permeable channel or channel regulator. Importantly, using a
pannexin 1-targeted mouse model, we demonstrated for the first
time that pannexin 1 mediates the release of ATP from a physio-
logically relevant tissue, i.e. freshly excised trachea (Fig. 4).
An additional important finding of the current study is the
identification of regulatory mechanisms upstream of pannexin
1-mediated ATP release. Given the non-selective large con-
ductance of pannexin 1 (64), strict control mechanisms should
be in place to regulate pannexin 1 activity under physiological
conditions to prevent collapse of the cellular ion gradients.
Recent studies demonstrated that irreversible opening of pan-
nexin 1 resulted in increased release of cellular ATP/UTP from
apoptotic T lymphocytes (50, 65). Therefore, an important goal
of our studies was to address whether responses attributed to
pannexin 1 in airway epithelia reflect a regulated function as
opposed to the irreversible opening of a plasmamembrane pore
and cell death.
Wehave addressed this question by demonstrating thatWD-
HBE and A549 cells exposed to a hypotonic solution exhibited
enhanced dye uptake only if the dye was added concurrently
with the hypotonic challenge; i.e. no changes in propidium
iodide uptake were observed if the dye was added to cells after
the isotonic conditions were restored (Fig. 5 and supplemental
Fig. 6). Thus, opening of the propidium iodide permeable
channel/pore during hypotonic cell swelling reflected a
reversible phenomenon rather than irreversible plasma
membrane damage.
Furthermore, regulatory components of the ATP release
response triggered by hypotonic cell swelling were identi-
fied. For example, we demonstrated that hypotonic stress
elicited RhoA activation and Rho kinase-dependent MLC
phosphorylation and that inhibition of RhoA activation, Rho
kinase, andMCL kinase decreased ATP release and impaired
dye uptake (Figs. 6–8). These results strongly suggest that
RhoA/Rho kinase activation (and subsequent MLC phos-
FIGURE 8. Rho-dependent regulation of dye uptake. A, representative images illustrating PI uptake in WD-HBE cells preincubated with vehicle, H1152, or
ML-7 (as in Fig. 5) and incubated for an additional 5 min with isotonic (Iso) or hypotonic (hypo) solutions in the presence of PI. B, quantification of PI uptake in
WD-HBE cells treated as in A. Data are the mean  S.E., n  4. Scale bar  200 m. C, PI uptake was measured (as above) in A549 cells transfected with empty
vector or RhoA(T19N). The results represent the mean  S.E. of four separate experiments performed in triplicate. *, significantly different from control (p 
0.05, B) or empty vector/hypotonic (p  0.01, C).
FIGURE 9. Hypotonic challenge-induced Rho activation and pannexin 1-mediated ATP release is sensitive to TRPV4 inhibitors. A, WD-HBE cells
were preincubated for 30 min with vehicle, 10 M ruthenium red (RuRed), or 10 M HC67047 followed by a 5-min hypotonic challenge, and ATP release
was measured as indicated under “Experimental Procedures.” *, p  0.05 against vehicle/hypotonic. B, cells were preincubated with 10 M HC67047 and
propidium iodide uptake was assessed as described in previous figures. Scale bar  200 m. The data (mean  S.E., n  4, right panel) are expressed as
the % maximal PI uptake in response to a hypotonic challenge. *, p  0.01. C, RhoA activation was measured in cells preincubated as above and
challenged for 5 min with isotonic or hypotonic solution. Data are mean  S.D., n  3. *, significantly different from vehicle/hypotonic, p  0.05.
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phorylation) is a step upstream of pannexin 1-mediated ATP
release in hypotonic stress-stimulated epithelia. These
results are consistent with the notion that hypotonic cell
swelling/stretch promotes Rho activity, as reported previously
with stretch-activated smooth muscle (66, 67), kidney mesangial
cells (68), and endothelial cells subjected to hypotonic stress (69,
70).
Our study also provides a clue to the potential mechanism by
which hypotonic challenge resulted in Rho activation.Wedem-
onstrated that TRPV4 channel inhibitors markedly impaired
hypotonicity-evoked Rho activation and reduce ATP release
and dye uptake in WD-HBE cells (Fig. 9), and we also showed
that knocking down TRPV4 reduced hypotonicity-promoted
ATP release (supplemental Fig. 8). The simplest interpretation
of our results is that TRPV4 channels transduce hypotonic cell
swelling into Rho activation. Themechanisms bywhichTRPV4
activate promotes Rho activation remain to be elucidated.
We have not addressed the mechanism by which Rho reg-
ulates pannexin 1-mediated ATP release. However, given the
actions exerted by Rho/Rho kinase on cytoskeletal compo-
nents (e.g. regulating MLC phosphorylation and actin
polymerization (71)), one speculation is that Rho-promoted
membrane-cytoskeletal rearrangements facilitate the inser-
tion of pannexin 1 (or a pannexin 1 regulator) within the
plasma membrane.
It is worth nothing, however, that pathways in addition to
pannexin 1 likely contribute to ATP release in WD-HBE cells.
Indeed, our results indicate that residual ATP release activity is
evident under conditions in which dye uptake has been com-
pletely or nearly completely abrogated by 10Panx1, ML-7, or
H1152. Observation of ATP release in the absence of dye
uptake together with the lack of effect of flufenamic acid (Fig. 1)
and the fact that incubations were in the presence of extracel-
lular 1.6 mM CaCl2 (a condition that inhibits connexin hemi-
channel opening (42, 72)) argues against the involvement of
connexins in the residual ATP release. Volume-regulated and
maxi anion channels (73) and vesicle exocytosis from non-mu-
cous cells (25, 74, 75) are potential mechanisms for pannexin1-
independent nucleotide release in hypotonic stress-stimulated
WD-HBE cells.
In sum, we have shown that pannexin 1 is an important
contributor to ATP release in hypotonic stress-stimulated
airway epithelia. Our data also indicate that hypotonic stress
induces Rho activation upstream of pannexin channel open-
ing and that TRPV4 channels likely transduce hypo-osmotic
stress into RhoA-promoted pannexin 1-mediated ATP
release.
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